EXECUTIVE INTERVIEWS

• A Q&A With Bernie Zeiher Of Astellas

  Bernie Zeiher Of Astellas took on the dual role of CMO & President of Development in April 2018. Here he discusses how he adjusted to that job and some of the best practices he’s learned along the way.

• The Making Of A CFO — A Conversation With J&J’s Joseph Wolk

  Joe Wolk’s father spent 40 years working at the nearby J&J manufacturing facility. Now, Joe has reached the top of the organization as CFO. His path getting there, though, didn’t start in pharma.

• 180 Life Sciences: Deliberately Seeking Serendipity

  At 180 Life Sciences, veterans of the old-pharma world are building a small bio enterprise focused evenly on scientific and market opportunities in the inflammation space.

• Enanta Pharmaceuticals: From Failure To Formidable

  While working at a VC firm, Jay Luly, Ph.D., was tasked with assessing if Enanta Pharmaceuticals could be turned around, or if it should be shut down. Today the company is probably one of the most productive Big Pharma R&D engines you’ve never heard of — until now.

• Inside The Planning Of Audentes' Future Manufacturing Facility

  A Q&A regarding Audentes Therapeutics’ Sanford, NC future facility, which will manufacture the company’s portfolio of adeno-associated virus (AAV)-based gene therapies aimed at targeting serious rare neuromuscular diseases.

• Canadian COVID Vax Comes Forward

  Long before the Warp Speed race, vaccines were a global business more characterized by collaboration than competition. In concert with its national regulator, Health Canada, IMV, Inc. could make world history with its approach to COVID vaccination.

• Position Your CDMO For Competitive Advantage

  “Outsourcing is really about positioning your CDMO to your competitive advantage,” says Lisa Wyman, SVP technical operations and quality at Acceleron Pharma.

• From Medical Researcher To CEO

  Yan Chen used her industry experience and interest in immunology to start Elpis Biopharmaceuticals, a company hoping to find cures for difficult-to-treat cancers.

• Two Immigrants, One Unique Plan For A Biopharma

  This is the story of how an intrapreneur and an entrepreneur came together to cofound and co-lead a pharmaceutical company that leverages the best of what the U.S. and China have to offer toward discovering and developing new oncology therapeutics.

• How A First-Time Pharma CEO Faces Hypergrowth

  Jeffrey Nau, Ph.D., discusses the career path that led him to becoming president and CEO of Oyster Point Pharma, a publicly traded biopharma now valued at more than $550 million and on the brink of commercial launch. 

• Frank Gupton – Revolutionizing Pharma Manufacturing From The Outside In

  “I’ve gotten more press during the last six and a half months than in my 68 years on this earth,” jokes Frank Gupton, Ph.D., a professor at Virginia Commonwealth University who has been involved in some key recent developments in pharma manufacturing.

• From “Musty Towel” To “Golden Age:” Biosimilars In 2021 And Beyond

  The industry has certainly come a long way since the “great doubt” of 2019. However, I’d argue the biosimilar space still remains on the verge of transformation.

• Politics and the Pandemic — Where Are They Taking Biopharma? Industry CEOs Speak Out

  Seventeen top executives of companies representing the entrepreneurial edge of biopharma innovation provide feedback on how the COVID-19 pandemic and the politics surrounding it could affect their companies’ futures and the industry.

• Can Your CDMO Relationships Survive Another “Virtual” Year?

  Lori Hoffman, head of alliance management, Slayback Pharma; and Greg Birrer, quality head, Elusys Therapeutics, talk about how the pandemic has affected CDMOs.